Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 9 | 2020 | 3157 | 0.340 |
Why?
|
| Health Care Surveys | 1 | 2002 | 295 | 0.180 |
Why?
|
| Fatigue | 1 | 2002 | 185 | 0.180 |
Why?
|
| Anemia | 1 | 2002 | 137 | 0.180 |
Why?
|
| Quality of Life | 3 | 2020 | 1816 | 0.180 |
Why?
|
| Mortality | 1 | 2002 | 154 | 0.170 |
Why?
|
| Capecitabine | 1 | 2020 | 99 | 0.160 |
Why?
|
| Flow Cytometry | 2 | 1992 | 728 | 0.150 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 244 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 209 | 0.140 |
Why?
|
| Severity of Illness Index | 1 | 2002 | 1981 | 0.130 |
Why?
|
| Patient Care Planning | 1 | 2015 | 89 | 0.110 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2012 | 37 | 0.110 |
Why?
|
| Self Care | 1 | 2015 | 170 | 0.110 |
Why?
|
| Neoplasms | 2 | 2015 | 3248 | 0.100 |
Why?
|
| Health Promotion | 1 | 2015 | 176 | 0.100 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 1670 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 228 | 0.100 |
Why?
|
| Radioisotope Teletherapy | 1 | 1992 | 4 | 0.100 |
Why?
|
| Mastectomy, Modified Radical | 1 | 1992 | 6 | 0.100 |
Why?
|
| Cobalt Radioisotopes | 1 | 1992 | 19 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 378 | 0.090 |
Why?
|
| Spectrophotometry | 1 | 1992 | 108 | 0.090 |
Why?
|
| Aromatase Inhibitors | 1 | 2012 | 32 | 0.090 |
Why?
|
| Arthralgia | 1 | 2012 | 41 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 2418 | 0.090 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1990 | 126 | 0.080 |
Why?
|
| Health Status | 1 | 2011 | 386 | 0.080 |
Why?
|
| Carcinoma | 1 | 1992 | 448 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2004 | 2642 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 2860 | 0.070 |
Why?
|
| Dietary Fats | 1 | 2006 | 137 | 0.060 |
Why?
|
| Female | 11 | 2020 | 50045 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 7230 | 0.050 |
Why?
|
| DNA | 1 | 1990 | 1333 | 0.050 |
Why?
|
| Middle Aged | 8 | 2020 | 28371 | 0.050 |
Why?
|
| Receptor, ErbB-3 | 1 | 2004 | 19 | 0.050 |
Why?
|
| Aged | 6 | 2020 | 20972 | 0.050 |
Why?
|
| Prognosis | 3 | 2020 | 4029 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 1 | 2004 | 280 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2015 | 1471 | 0.050 |
Why?
|
| Adult | 6 | 2020 | 28725 | 0.040 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.040 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 28 | 0.040 |
Why?
|
| Ploidies | 2 | 1990 | 41 | 0.040 |
Why?
|
| Humans | 11 | 2020 | 96112 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 3927 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 1429 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 1992 | 1773 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 382 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2006 | 514 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1882 | 0.030 |
Why?
|
| Transitional Care | 1 | 2015 | 20 | 0.030 |
Why?
|
| Survivors | 1 | 2015 | 204 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2004 | 1546 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2011 | 2086 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2015 | 198 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 180 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2006 | 1196 | 0.020 |
Why?
|
| United States | 2 | 2004 | 7768 | 0.020 |
Why?
|
| Risk Factors | 2 | 2015 | 5961 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 2494 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 1992 | 313 | 0.020 |
Why?
|
| Androstadienes | 1 | 2012 | 74 | 0.020 |
Why?
|
| Nitriles | 1 | 2012 | 157 | 0.020 |
Why?
|
| Doxorubicin | 1 | 1992 | 304 | 0.020 |
Why?
|
| Outpatients | 1 | 2012 | 105 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 4672 | 0.020 |
Why?
|
| Triazoles | 1 | 2012 | 110 | 0.020 |
Why?
|
| Fluorouracil | 1 | 1992 | 555 | 0.020 |
Why?
|
| History, 20th Century | 1 | 1992 | 327 | 0.020 |
Why?
|
| Male | 3 | 2015 | 45871 | 0.020 |
Why?
|
| Oncogenes | 1 | 1989 | 100 | 0.020 |
Why?
|
| Axilla | 1 | 1989 | 110 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 1990 | 417 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1989 | 298 | 0.020 |
Why?
|
| Cell Division | 1 | 1989 | 705 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2011 | 408 | 0.020 |
Why?
|
| Incidence | 1 | 2012 | 1715 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2012 | 10287 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2011 | 9176 | 0.020 |
Why?
|
| Carcinoma, Lobular | 1 | 2006 | 85 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 1989 | 565 | 0.010 |
Why?
|
| Body Weight | 1 | 2006 | 460 | 0.010 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2006 | 166 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2006 | 884 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 901 | 0.010 |
Why?
|
| Trastuzumab | 1 | 2004 | 88 | 0.010 |
Why?
|
| Taxoids | 1 | 2004 | 131 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 366 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1989 | 1667 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 7025 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2004 | 740 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2004 | 1346 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2004 | 1021 | 0.010 |
Why?
|